699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results

BACKGROUND: LEF efficacy and safety were shown in 2 noninferiority trials (LEAP 1/2) vs. MOX in adults with CABP. We assessed the hepatobiliary safety of LEF based on pooled analyses of LEAP 1/2 data. METHODS: In LEAP 1, PORT III–V patients received LEF 150 mg IV q12h for 5–7 days or MOX 400 mg IV q...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, James H, Das, Anita F, Stein, Daniel, Gelone, Steven P, Schranz, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811256/
http://dx.doi.org/10.1093/ofid/ofz360.767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811256/
http://dx.doi.org/10.1093/ofid/ofz360.767

Ejemplares similares